key: cord-0924948-ltfuzsbb
authors: Pranata, Raymond; Supriyadi, Rudi; Huang, Ian; Permana, Hikmat; Lim, Michael Anthonius; Yonas, Emir; Soetedjo, Nanny Natalia M; Lukito, Antonia Anna
title: The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis
date: 2020-09-17
journal: Clin Med Insights Circ Respir Pulm Med
DOI: 10.1177/1179548420959165
sha: 2170d58cdb4bf56ee0cda371b957f50e8c736560
doc_id: 924948
cord_uid: ltfuzsbb

OBJECTIVE: The aim of the study was to evaluate the association between chronic kidney disease (CKD) and new onset renal replacement therapy (RRT) with the outcome of Coronavirus Disease 2019 (COVID-19) in patients. METHODOLOGY: A systematic literature search from several databases was performed on studies that assessed CKD, use of RRT, and the outcome of COVID-19. The composite of poor outcome consisted of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care, and use of mechanical ventilator. RESULTS: Nineteen studies with a total of 7216 patients were included. CKD was associated with increased composite poor outcome (RR 2.63 [1.33, 5.17], P = .03; I(2) = 51%, P = .01) and its subgroup, consisting of mortality (RR 3.47 [1.36, 8.86], P = .009; I(2) = 14%, P = .32) and severe COVID-19 (RR 2.89 [0.98, 8.46], P = .05; I(2) = 57%, P = .04). RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25], P < .001; I(2) = 87%, P < .001), including mortality (RR 26.02 [5.01, 135.13], P < .001; I(2) = 60%, P = .06), severe COVID-19 (RR 12.95 [1.93, 86.82], P = .008; I(2) = 81%, P < .001), intensive care (IC) (RR 14.22 [1.76, 114.62], P < .01; I(2) = 0%, P < .98), and use of mechanical ventilator (RR 34.39 [4.63, 255.51], P < .0005). CONCLUSION: CKD and new-onset RRT were associated with poor outcome in patients with COVID-19.

Coronavirus Disease 2019 (COVID-19) is a global health concern requiring special attention. The cases of COVID-19 and deaths attributed to it are increasing every day; over 19 000 000 cases and 700 000 deaths have been documented as of 8 August 2020. 1 We may consider COVID-19 as a relatively benign illness since the majority of COVID-19 patients have only mild influenza-like symptoms; however, a minority of the patients may present with multi-organ failure, necessitating more advanced interventions such as the use of mechanical ventilator and renal replacement therapy (RRT). 2 Advanced age and several comorbidities were found to be associated with severe COVID-19. [3] [4] [5] [6] [7] [8] Therefore, identifying all independent risk factors to predict COVID-19 severity is essential during this pandemic, 9 when intensive care may not be readily available.

Although chronic kidney disease (CKD) was apparently not as prevalent as other comorbidities in COVID-19 patients, it has been associated with increased risk of mortality and severe COVID-19 in a relatively small sample of patients (Bai, Tu and Wei, 2020) . 10 It was hypothesized that increased angiotensin converting enzyme 2 (ACE2) levels in patients with CKD was associated with the increased risk of mortality and severe COVID-19. It was previously shown that CKD patients have increased levels of ACE2, which facilitates the entry of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) into human cells. 12 The need for RRT in COVID-19 patients was also reportedly associated with poor outcome 11 ; however, whether the risk of poor outcome was affected by the underlying CKD or other comorbidities is unknown. In the present study, a systematic review and meta-analysis was conducted to investigate the

Systematic literature search was performed through PubMed, SCOPUS, EuropePMC, and Cochrane Central Database with several search terms, including: (1) ("COVID-19" OR "SARS-CoV-2") AND "Characteristics" AND ("Mortality" OR "SEVERE"), (2) ("COVID-19" OR "SARS-CoV-2") AND "Characteristics", (3) ("COVID-19" OR "SARS-CoV-2") AND "Chronic Kidney Disease", (4) ("COVID-19" OR "SARS-CoV-2") AND "Renal Replacement Therapy." All duplicate results were then removed. The abstracts of the returned articles were screened and subsequently, the full texts of the potentially eligible articles were evaluated. The systematic search was completed on 23 April 2020. The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

A standardized criteria was used for data collection in this meta-analysis. The variables considered were: author, year, study design, sex, age, presence of comorbidities (including hypertension, diabetes, cardiovascular disease, respiratory comorbidities, CKD), baseline serum creatinine level, use of RRT, and the outcome of interest. The outcome of interest, which was composite poor outcome, included mortality, severe COVID-19, ARDS, need for intensive care, and the use of mechanical ventilator. Mortality was defined as death during hospitalization, while severe COVID-19 was defined according to the Report of the WHO-China Joint Mission on COVID-19 (respiratory rate ⩾30 times per min, oxygen desaturation ⩽93% without supplementation, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air [PaO2/FiO2] ratio ⩽300 mm Hg, or the presence of any of the following: respiratory failure, septic shock, or multi organ failure). 13 ARDS was defined according to the WHO interim guidance of severe acute respiratory infection (SARI) of COVID-19. 14 Intensive care and the use of mechanical ventilator were defined as admission to intensive care unit (ICU) regardless of the reasons and the use of mechanical ventilation, respectively.

All dichotomous variables were calculated using the Mantel-Haenszel method with random-effects model, irrespective of heterogeneity. Heterogeneity among the included studies was evaluated using the I 2 and chi square (χ 2 ) test. Significant heterogeneity was considered as I 2 test >50% with a χ 2 P-value <.05. Risk ratios (RRs) and mean differences (MD) with 95% confidence intervals (CIs) were used for dichotomous and continuous variables, respectively. The P-value was 2-tailed and values ⩽.05 were considered statistically significant. Random effects meta-regression was performed using restricted-maximum likelihood for age, sex, cardiovascular disease, hypertension, respiratory comorbidities, and diabetes. Regression-based Harbord's test for binary outcome was used to measure small study effect, while the risk of publication bias was evaluated using Begg's funnel plot analysis. All statistical analyses were performed using Review Manager 5.3 (Cochrane Collaboration) and Stata ® 16.

The study flow chart used in this analysis is presented in Figure 1 . Initially, 767 results were identified through all search engines. After the removal of duplicate results, 693 records remained. A total of 627 results were excluded after screening titles and abstracts. After assessing 66 full-text articles for eligibility, 47 articles were further excluded because: (1) no data on CKD patients or RRT were available (n = 30) and (2) the groups were not divided based on the outcome of interest (n = 17). Thus, 19 studies including a total of 7216 patients were included in the qualitative synthesis and metaanalysis (Table 1) 

Meta-analysis showed that CKD was associated with increased composite poor outcome (RR 2.63 [1.33, 5.17], P = .03; I 2 : 51%, P = .01). Subgroup analysis in CKD patients also showed significantly increased risk for mortality, as shown in Figure 2 

The new onset RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25] , P < .001; I 2 : 87%, P < .001). Subgroup analysis also showed significantly increased risk for mortality ( 

Meta-regression showed that the association between CKD and composite poor outcome was not influenced by sex (P = .803), respiratory comorbidities (P = .104), and RRT (P = .164), but was significantly affected by age (P = .019), hypertension (P = .019), cardiovascular diseases (P = .041), and diabetes (P = .001). In contrast, the meta-regression analysis on the association between RRT and composite poor outcome was not affected by any variables, including age (P = .623), sex (P = .731), cardiovascular diseases (P = .170), hypertension (P = .551), diabetes (P = .375), respiratory comorbidities (P = .697), and CKD (P = .668).

Funnel plots were asymmetrical for the association of both CKD (Figure 3(a) ) and RRT (Figure 3 (b)) with composite poor outcome. Regression-based Harbord's test showed a statistically 

This meta-analysis showed that CKD was associated with and presents approximately 3-fold higher risk of mortality and severe COVID-19. Meta-regression analysis showed that the association between CKD and COVID-19 outcome was affected by age, hypertension, cardiovascular diseases, and diabetes. The results of this study reinforce our previous theory on the intertwined relationships of hypertension, diabetes, age, and CKD with the severe COVID-19, 3,4 culminating in the rationalization of renin-angiotensin system (RAS) signaling and angiotensin converting enzyme 2 (ACE2). It was demonstrated that individuals with CKD have increased levels of circulating ACE2, 12 which facilitates the entry of SARS-CoV-2 and may later be downregulated by the virus, leading to unregulated angiotensin-2 activity and multiple (Continued) 6 Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine organ failure. 15, 33, 34 Moreover, the baseline serum creatinine levels of most patients included in this study were within the normal reference range. This might indicate that having early-stage CKD may increase the risk of poor outcome in COVID-19; however, further studies regarding the association between CKD stage and poor outcome must be sought.

Other remarkable variables of interest that should be included in the analysis were the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) for hypertension, CKD, and cardiovascular disease. There have been speculations that these drug classes may reduce the severity of COVID-19; previous studies showed that the use of ACEI/ARB in hypertensive individuals was associated with a significant decrease in mortality of COVID-19 patients. 35, 36 It was unfortunate that the data on these drug classes were lacking in all the included studies.

RRT is an advanced intervention in patients with kidney injury that is seldom reported in COVID-19 patients. 2, 25, 26 In this meta-analysis, we found that new-onset RRT was significantly associated with composite poor outcome, including mortality, severity, need for intensive care, ARDS, and the use of mechanical ventilator in patients with COVID-19. The increased risk for mortality was more than 25-fold compared to COVID-19 patients not receiving RRT. An interesting finding 7 of this meta-regression analysis was that there were no variables that affected the association between RRT and poor outcome, including age, sex, cardiovascular diseases, hypertension, diabetes, respiratory comorbidities, and CKD.

A logical explanation for these findings is the direct effect of SARS-COV-2 on the kidney due to the abundant expression of ACE2 in tubular cells of the kidney. 37 Another possible explanation is that the hyper-inflammatory response caused by cytokine storms, rather than the direct invasion by SARS-CoV-2, is the primary causative of multi-organ failure including kidney injury. 38 The impact of early versus late RRT initiation in critically ill patients with AKI is a contentious issue that is important to explore. Randomized controlled trial (RCT) in non-COVID-19 patients showed that early initiation of continuous renal replacement therapy (CRRT) within 8 hours following AKI stage II is associated with a significantly lower 90-days mortality rate compared to patients receiving CRRT within 12 hours after AKI Stage III diagnosis. 39 Conversely, another RCT reported no differences in terms of 90-days mortality between the approaches. Although a recent meta-analysis showed no mortality benefits between the 2 strategies, they note that the contradictory evidence is due to substantially heterogeneous definition of CRRT timing and dosing among the trials. 40 Unfortunately, all of the included studies in this meta-analysis did not report the timing of RRT initiation. Thus, the supposition whether the timing of RRT initiation might affect the outcome of COVID-19 patient cannot be explored by our study.

In the context of cytokine storm syndrome (CSS) with AKI and multi-organ failure in severe COVID-19, 41, 42 there is a growing interest in using cytokine filtration through the extracorporeal techniques, including the high cutoff (HCO) membrane and CytoSorb. 43 Both blood purification strategies are considered effective in reducing inflammatory cytokines (especially IL-6), 44 but whether these approaches can effectively reduce mortality and severity in patients with COVID-19 is still unknown. In the absence of established treatment options for COVID-19, experts across the globe recommended these approaches to facilitate cytokine clearance. 44, 45 Other contentious issue concerning the RRT among patients with severe COVID-19 is the type of anticoagulation used during the process of RRT. Hypercoagulable state is considered as a hallmark of severe COVID-19 as depicted by the increased of serum D-dimer values and high rate of blood circuit failures in the process of RRT. 41,46,47 While regional citrate anticoagulation has been universally used in CRRT because of its efficacy in terms of prolonging the extracorporeal circuit lifespan and decreasing the risk of bleeding, 45 it has not been demonstrated to be as effective in COVID-19 as in other patients. 47 Furthermore, the discovery of the mortality benefits using heparin-based anticoagulation approach leads to a further question whether this citrate-based anticoagulation in CRRT is the best approach in patients with severe COVID-19. 48 This current study reinforced previous meta-analyses concerning the association of renal impairment with severity of COVID-19. 49, 50 Henry and Lippi reported in their meta-analysis that the presence of CKD are associated with severe COVID-19; however, they only included 4 studies with a total of 1389 COVID-19 patients. 49 Meanwhile, Ali et al showed that the presence of severe AKI is associated with high mortality among patients with COVID-19. 50 However, their metaanalysis only included 2 studies which required RRT. On the other hand, our meta-analysis included more studies with relatively higher samples and further meta-regression analysis which was not previously conducted. Thus, the evidence of the association between CKD and RRT with poor outcome is further strengthened by our findings.

The limitation of this meta-analysis was the presence of publication bias for both CKD and RRT on composite poor outcome, which was apparent in the asymmetrical funnel plot analysis. In addition, there were small-study effects for CKD. The inclusion of studies that were published in preprint servers and not yet peer-reviewed may be a limitation; nevertheless, we considered the studies as potential addition to the current literature. Moreover, the retrospective and observational nature of the included studies warrant careful interpretation in our findings. 

CKD and RRT were associated with composite poor outcome in patients with COVID-19. Although the risk for poor outcome was affected by other comorbidities associated with the RAS system, the presence of CKD should still be investigated when admitting patients with COVID-19, as it increases the risk of severe disease and mortality. Furthermore, the baseline serum creatinine level in most patients included in this study was within the normal reference range. This might possibly indicate that even early-stage CKD can increase the risk of poor outcome in patients with COVID-19. Furthermore, the presence of complications that necessitated RRT was associated with a more than 25-fold increased risk of mortality in COVID-19 patients.

CKD and RRT are associated with poor outcome in patients with COVID-19. The association between CKD and poor outcome in COVID-19 was influenced by other variables that might be interconnected with RAS.

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report -201

Clinical characteristics of coronavirus disease 2019 in China

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19 -Systematic review, meta-analysis, and meta-regression

Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

Body mass index and outcome in patients with COVID-19: a dose-response meta-analysis

Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis

Clinical and laboratory factors predicting the prognosis of patients with COVID-19: an analysis of 127 patients in Wuhan

Acute kidney injury in patients hospitalized with COVID-19

Circulating ACE2 in cardiovascular and kidney diseases

Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical characteristics of SARS-CoV-2 infections involving 325 hospitalized patients outside Wuhan

Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical features and treatment of COVID-19 patients in northeast chongqing

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical characteristics of Covid-19 in New York city

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China

Clinical characteristics and risk factors for fatal outcome in patients with 2019-coronavirus infected disease (COVID-19) in Wuhan

Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area

Risk factors associated with clinical outcomes in 323

COVID-19) hospitalized patients in Wuhan, China

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis

Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the elain randomized clinical trial

Early versus late initiation of renal replacement therapy for acute kidney injury in critically ill patients: a systematic review and meta-analysis

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a metaanalysis

Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis

Cytokine Blood Filtration Responses in COVID-19

Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?

Management of acute kidney injury in patients with COVID-19

Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?

Preparedness of kidney replacement therapy in the critically ill during COVID-19 surge

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis

RP, RS, IH, and HP designed the study. RP and IH collected the data, drafted the manuscript, and accomplished data extraction and interpretation. AAL, RS, HP, IH, MAL, and EY performed extensive research. AAL, RS, HP, and NNMS critically reviewed and edited the manuscript. All authors contributed to the writing of the manuscript. RP performed the statistical analyses.

https://orcid.org/0000-0003-3998-6551Michael Anthonius Lim https://orcid.org/0000-0001-7631-6835